2026/03/11 更新

写真a

マツウラ　トモカ
松浦　知香
Matsuura Tomoka
担当
大学院医学研究科 基礎医科学専攻 助教
医学部 医学科
職名
助教
所属
医学研究院
所属キャンパス
阿倍野キャンパス

担当・職階

  • 大学院医学研究科 基礎医科学専攻 

    助教  2022年04月 - 継続中

  • 医学部 医学科 

    助教  2022年04月 - 継続中

取得学位

  • 医学博士 （ 大阪市立大学 ）

研究分野

  • ライフサイエンス / 衛生学、公衆衛生学分野：実験系を含む  / 新型コロナウイルス、ワクチン、肝疾患、消化器疾患

研究キーワード

  • 消化器疾患

  • 公衆衛生学

  • ワクチン疫学

所属学協会

  • 日本疫学会

    2022年10月

  • 日本ワクチン学会

    2021年09月 - 継続中

  • 日本消化器内視鏡学会

    2020年06月

  • 日本公衆衛生学会

    2018年08月

  • 日本肝臓学会

    2016年07月

  • 日本消化器病学会

    2011年04月 - 継続中

  • 日本内科学会

    2010年04月 - 継続中

▼全件表示

職務経歴（学外）

  • 大阪公立大学   大学院医学研究科 公衆衛生学

    2021年04月 - 継続中

論文

  • Adverse reactions following first three doses of the BNT162b2 mRNA COVID-19 vaccine: A prospective cohort study on relationships with individual characteristics and previous experience of adverse reactions.

    Ayako Konishi, Wakaba Fukushima, Tomoka Matsuura, Satoko Ohfuji, Tetsuo Kase, Kyoko Kondo, Kazuhiro Matsumoto, Asae Suita, Emiko Mukai, Ayane Kasamatsu, Yasutoshi Kido, Yu Nakagama, Yuko Nitahara, Yukihiro Kaneko, Akira Kaneko, Etsuko Nakagami-Yamaguchi, Hiroshi Kakeya, Yoshio Hirota

    Human vaccines & immunotherapeutics   21 ( 1 )   2518646 - 2518646   2025年12月

    　詳細を見る

    掲載種別：研究論文（学術雑誌）   国際・国内誌：国際誌  

    A clear consensus on the factors contributing to adverse reactions following the mRNA COVID-19 vaccine has yet to be reached. Therefore, the present study investigated adverse reactions following the first three doses of the BNT162b2 mRNA COVID-19 vaccine and examined associated factors, including previous experience of adverse reactions. Two prospective cohort studies were integrated for this study, and 218 participants (79% female; median age 46.5 years) who had completed all three doses of BNT162b2 were included in the final analyses. Data were collected through self-administered electronic questionnaires. Local and systemic adverse reactions following vaccinations were classified with severity grading. Modified Poisson regression models were used to examine the association of adverse reactions. Local reactions were reported by 91-96% of participants, with moderate or severe local reactions in 27-43%. Systemic reactions were reported by 56-88% of participants, with moderate or severe systemic reactions in 19-56%. Participants with a history of moderate or severe local reactions were more likely to subsequently have moderate or severe local reactions (relative risk: 2.32 [95% confidence interval: 1.52-3.55] for the second dose, 1.89 [1.33-2.69] for the third dose), but not systemic reactions. Participants with a history of moderate or severe systemic reactions were more likely to subsequently have moderate or severe systemic reactions (1.31 [0.99-1.72] for the second dose, 2.18 [1.56-3.06] for the third dose), but not local reactions. These results may contribute to a more detailed understanding of mRNA COVID-19 vaccines and provide information for future vaccine development.

    DOI： 10.1080/21645515.2025.2518646

    PubMed

  • Durability of antibody titers and associated factors after the booster dose of COVID-19 mRNA vaccination in Japanese SARS-CoV-2 infection-naive residents in geriatric intermediate care facilities.

    Ayane Kasamatsu, Satoko Ohfuji, Asae Suita, Kyoko Kondo, Hiroyuki Nakata, Tetsuya Kita, Akifumi Deguchi, Mikio Fujimoto, Kazuko Iba, Hideki Sakamoto, Kaori Iwasaka, Noboru Sakamoto, Hikaru Sakamoto, Yoshiko Yodoi, Yasutoshi Kido, Yu Nakagama, Ayako Konishi, Emiko Mukai, Kazuhiro Matsumoto, Tomoka Matsuura, Tetsuo Kase, Hiroshi Kakeya, Wakaba Fukushima, Yoshio Hirota

    Geriatrics & gerontology international   25 ( 4 )   588 - 597   2025年04月

    　詳細を見る

    掲載種別：研究論文（学術雑誌）   国際・国内誌：国内誌  

    AIM: Elderly adults are at higher risk for severe COVID-19 infection. This multicenter, prospective cohort study assessed immunogenicity after COVID-19 vaccinations in elderly residents compared with staff in geriatric intermediate care facilities. Predictors of lower antibody titers were also examined. METHODS: Fifty-four residents and 117 staff who had received three doses of the COVID-19 mRNA vaccine between March 2021 and September 2022 were included. Anti-receptor binding domain antibody titers were measured 3-4 weeks and 6 months after the vaccinations. Adjusted geometric mean titers (GMT) were calculated using multivariable linear mixed effects models. RESULTS: After the first dose, residents had a significantly lower adjusted GMT than did staff (115 vs. 267 AU/mL, P < 0.01), whereas the adjusted GMT of residents was comparable to that of staff after the third dose (14 178 vs. 12 159 AU/mL, P = 0.63). However, 6 months later, the adjusted GMT of residents was less than half that of staff (1645 vs. 4302 AU/mL, P < 0.01). In residents, steroid users had a significantly lower adjusted GMT than did steroid nonusers. CONCLUSIONS: The third dose of mRNA vaccine boosted the immune response of elderly residents. However, their antibody titers, particularly in steroid users, were highly attenuated 6 months after the last vaccination. For this population, attention should be focused on additional vaccinations. Geriatr Gerontol Int 2025; 25: 588-597.

    DOI： 10.1111/ggi.70028

    PubMed

  • Cross-Reactive Fc-Mediated Antibody Responses to Influenza HA Stem Region in Human Sera Following Seasonal Vaccination 査読

    Ayae Nishiyama, Takuto Nogimori, Yuji Masuta, Tomoka Matsuura, Tetsuo Kase, 近藤亨子, Satoko Ohfuji, Yu Nakagama, Natsuko Kaku, Sachie Nakagama, Yuko Nitahara, Yoshimasa Takahashi, Hiroshi Kakeya, Yasutoshi KIDO, Wakaba Fukushima, Takuya Yamamoto

    Vaccines   2025年01月

    　詳細を見る

    掲載種別：研究論文（学術雑誌）  

    DOI： 10.3390/vaccines13020140

  • COVID-19 mRNAワクチンが誘導する記憶CD8T細胞の長期維持機構の解明

    野木森 拓人, 升田 雄士, 松浦 知香, 加瀬 哲男, 熊本 舞夢, 高濱 正吉, 近藤 亨子, 大藤 さとこ, 中釜 悠, 城戸 康年, 福島 若葉, 山本 拓也

    臨床とウイルス   52 ( 3 )   144 - 144   2024年10月（ ISSN:0303-8092 ）

  • BNT162b2 mRNA COVID-19ワクチン接種後副反応の関連因子

    小西 絢子, 福島 若葉, 松浦 知香, 大藤 さとこ, 加瀬 哲男, 近藤 享子, 吹田 安佐詠, 迎 恵美子, 笠松 彩音, 掛屋 弘, 城戸 康年, 中釜 悠, 加来 奈津子, 金子 幸弘, 廣田 良夫

    臨床とウイルス   52 ( 3 )   174 - 174   2024年10月（ ISSN:0303-8092 ）

  • Factors impacting antibody kinetics, including fever and vaccination intervals, in SARS-CoV-2-naïve adults receiving the first four mRNA COVID-19 vaccine doses.

    Tomoka Matsuura, Wakaba Fukushima, Yu Nakagama, Yasutoshi Kido, Tetsuo Kase, Kyoko Kondo, Natsuko Kaku, Kazuhiro Matsumoto, Asae Suita, Emiko Mukai, Yuko Nitahara, Ayako Konishi, Ayane Kasamatsu, Sachie Nakagama, Etsuko Nakagami-Yamaguchi, Satoko Ohfuji, Yukihiro Kaneko, Akira Kaneko, Hiroshi Kakeya, Yoshio Hirota

    Scientific reports   14 ( 1 )   7217 - 7217   2024年03月

    　詳細を見る

    掲載種別：研究論文（学術雑誌）   国際・国内誌：国際誌  

    To evaluate the antibody response following the initial four doses of mRNA vaccines (BNT162b2 or mRNA-1273) in SARS-CoV-2-naïve healthy adults and investigate factors influencing antibody titer increases, this prospective cohort study was conducted in Japan from March 2021. The study included participants who received either the 1st and 2nd doses (n = 467), 3rd dose (n = 157), or 4th dose (n = 89). Blood samples were collected before and up to 6 months after each dose, and anti-receptor-binding domain antibody levels were measured. Multivariate analysis (usin multiple linear regression or linear mixed models) revealed several factors significantly associated with higher post-vaccination antibody levels, including mRNA-1273 vaccine (after the 1st and 2nd dose), male gender (after the 3rd and 4th doses), younger age (after the 1st and 2nd dose), non-smoking status (after the 2nd dose), non-use of immunosuppressive agents (after the 1st dose), higher pre-vaccination antibody titers (after the 2nd, 3rd, and 4th doses), and higher post-vaccination fever (after the 2nd and 4th doses). Furthermore, longer intervals since the last dose were significantly associated with higher antibody levels after the 3rd and 4th doses. These findings provide valuable insights for optimizing vaccination strategies.

    DOI： 10.1038/s41598-024-57931-0

    PubMed

▼全件表示

講演・口頭発表等

▼全件表示

科研費獲得実績

  • 原発性胆汁性胆管炎の予後に関する分析疫学研究

    基盤研究(C)  2027年

  • 原発性胆汁性胆管炎の予後に関する分析疫学研究

    基盤研究(C)  2026年

  • Budd-Chiari症候群の予後に関する分析疫学研究

    基盤研究(C)  2025年

  • 原発性胆汁性胆管炎の予後に関する分析疫学研究

    基盤研究(C)  2025年

  • 新型コロナウイルスワクチンの抗体応答の関連因子：メタボロミクスに着目した検討

    基盤研究(B)  2024年

  • Budd-Chiari症候群の予後に関する分析疫学研究

    基盤研究(C)  2024年

▼全件表示

担当授業科目

  • 研究指導

    2025年度   集中講義   大学院

  • 発表表現演習

    2025年度   集中講義   大学院

  • 公衆衛生学（公衆衛生学研究読解演習）

    2025年度   集中講義   大学院

  • 公衆衛生学（公衆衛生学研究計画演習）

    2025年度   集中講義   大学院

  • 公衆衛生学（公衆衛生対策）

    2025年度   集中講義   大学院

  • 公衆衛生学（疫学データ解析講習）

    2025年度   集中講義   大学院

  • 公衆衛生学（公衆衛生学応用）

    2025年度   集中講義   大学院

  • 公衆衛生学（公衆衛生学基礎）

    2025年度   集中講義   大学院

  • 特別研究

    2025年度   集中講義   大学院

  • 都市医学演習（公衆衛生学）

    2025年度   集中講義   大学院

  • 都市医学（公衆衛生学）

    2025年度   集中講義   大学院

▼全件表示

学外での担当授業科目

  • 公衆衛生学

    2022年04月
    -
    継続中
    機関名：大阪公立大学 大学院医学研究科